935 results on '"Fietkau R"'
Search Results
2. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
3. F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial
4. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations: An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO)
5. Neoadjuvant concurrent chemoradiotherapy with and without hyperthermia in retroperitoneal sarcomas: feasibility, efficacy, toxicity, and long-term outcome
6. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial
7. Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108)
8. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial
9. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial
10. Penile bulb sparing in prostate cancer radiotherapy: Dose analysis of an in-house MRI system to improve contouring
11. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine
12. Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience
13. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma – results of the Conko-007 multicenter trial
14. Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report
15. Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients
16. Lethal outcome after pelvic salvage radiotherapy in a patient with prostate cancer due to increased radiosensitivity: Case report and literature review
17. Novel technique for high-precision stereotactic irradiation of mouse brains
18. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy
19. Re-irradiation of the chest wall for local breast cancer recurrence: Results of salvage brachytherapy with hyperthermia
20. Clinically significant CMV (re)activation during or after radiotherapy/chemotherapy of the brain: Correlation with neurological deterioration and improvement upon antiviral treatment
21. DEGRO practical guidelines for radiotherapy of breast cancer VI: therapy of locoregional breast cancer recurrences
22. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study
23. 1247P Radiotherapy (RT) patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients (pts) with Stage III unresectable non-small cell lung cancer (UR-NSCLC) treated with durvalumab (D) after chemoradiotherapy (CRT)
24. TIGER PRO-Active study – investigating daily activity, sleep and neurocognitive functioning in glioblastoma patients applying TTFields therapy in Germany in routine clinical care
25. First results of the TIGER study – treatment decision and quality of life of glioblastoma patients during TTFields therapy in routine clinical care
26. Radiochemotherapy induces a favourable tumour infiltrating inflammatory cell profile in head and neck cancer
27. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations
28. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC)
29. The Erlangen Dose Optimization Trial for radiotherapy of benign painful shoulder syndrome: Long-term results
30. DEGRO practical guidelines: radiotherapy of breast cancer III—radiotherapy of the lymphatic pathways
31. The Erlangen Dose Optimization trial for low-dose radiotherapy of benign painful elbow syndrome: Long-term results
32. Dose-dependent deterioration of swallowing function after induction chemotherapy and definitive chemoradiotherapy for laryngopharyngeal cancer
33. DEGRO practical guidelines: radiotherapy of breast cancer II: Radiotherapy of non-invasive neoplasia of the breast
34. Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients
35. Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function
36. Radiochemotherapy for Bladder Cancer
37. DEGRO practical guidelines: radiotherapy of breast cancer I: Radiotherapy following breast conserving therapy for invasive breast cancer
38. Protocol-based image-guided salvage brachytherapy: Early results in patients with local failure of prostate cancer after radiation therapy
39. Radiotherapy for calcaneodynia: Results of a single center prospective randomized dose optimization trial
40. Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy?: Statement of the German and the Austrian Societies of Radiooncology (DEGRO/ÖGRO)
41. Radiotherapy for achillodynia: Results of a single-center prospective randomized dose-optimization trial
42. Rectal cancer: When is the local recurrence risk low enough to refrain from the aim to prevent it?
43. Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115)
44. ELDORANDO : Pembrolizumab compared with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115)
45. When are breast cancer patients old enough for the quitclaim of local control?
46. Benign painful shoulder syndrome: Initial results of a single-center prospective randomized radiotherapy dose-optimization trial
47. Benign painful elbow syndrome: First results of a single center prospective randomized radiotherapy dose optimization trial
48. Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients: The DEGRO-QUIRO trial
49. Radiosensitizing effect of epothilone B on human epithelial cancer cells
50. Chemoradiotherapy duration correlates with overall survival in limited disease SCLC patients with poor initial performance status who successfully completed multimodality treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.